Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Account Payables (2020 - 2025)

Lyell Immunopharma's Change in Account Payables history spans 6 years, with the latest figure at -$779000.0 for Q3 2025.

  • For Q3 2025, Change in Account Payables fell 37.15% year-over-year to -$779000.0; the TTM value through Sep 2025 reached -$4.7 million, down 508.02%, while the annual FY2024 figure was -$3.2 million, 320.9% down from the prior year.
  • Change in Account Payables for Q3 2025 was -$779000.0 at Lyell Immunopharma, down from -$231000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.9 million in Q1 2022 and bottomed at -$2.0 million in Q4 2024.
  • The 5-year median for Change in Account Payables is -$231000.0 (2025), against an average of -$193473.7.
  • The largest annual shift saw Change in Account Payables surged 363.25% in 2022 before it tumbled 6230.43% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at $99000.0 in 2021, then plummeted by 631.31% to -$526000.0 in 2022, then soared by 180.8% to $425000.0 in 2023, then crashed by 579.06% to -$2.0 million in 2024, then soared by 61.74% to -$779000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Change in Account Payables are -$779000.0 (Q3 2025), -$231000.0 (Q2 2025), and -$1.7 million (Q1 2025).